NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study

• Published in: Ophthalmology (Rochester, Minn.) Vol. 130; no. 5; pp. 516 - 524
• Main Authors: Tauber, Joseph, Berdy, Gregg J, Wirta, David L, Krösser, Sonja, Vittitow, Jason L
• Format: Journal Article
• Language: English
• Published: United States 01.05.2023
• Subjects: Adult; Double-Blind Method; Dry Eye Syndromes - diagnosis; Dry Eye Syndromes - drug therapy; Dry Eye Syndromes - etiology; Fluorescein; Humans; Meibomian Gland Dysfunction; Meibomian Glands; Ophthalmic Solutions; Tears; NOV03; Perfluorohexyloctane; Clinical trial; Dry eye disease; Meibomian gland dysfunction
• ISSN: 1549-4713
• DOI: 10.1016/j.ophtha.2022.12.021

To evaluate the efficacy and safety of NOV03 (perfluorohexyloctane) ophthalmic drop in patients with dry eye disease (DED) associated with meibomian gland dysfunction (MGD). Eight-week, phase 3, multicenter, randomized, double-masked, saline-controlled study. Adults ≥ 18 years with a history of DED for ≥ 6 months, tear film breakup time of ≤ 5 seconds, Schirmer I test (without anesthesia) score ≥ 5 mm, MGD score ≥ 3 (0-15 scale), and total corneal fluorescein staining (tCFS) score ≥ 4 and ≤ 11 (0-15 National Eye Institute [NEI] scale). Patients were randomized 1:1 to NOV03 or hypotonic (0.6%) saline 4 times daily. The primary sign and symptom end points were change from baseline in tCFS and eye dryness score (0-100 visual analog scale [VAS]) at week 8. Key secondary end points were change from baseline in eye dryness score at week 2, tCFS at week 2, eye burning or stinging score (0-100 VAS) at week 8, and central corneal fluorescein staining (cCFS; 0-3 NEI scale) at week 8. Of the 599 patients randomized, 597 were treated (NOV03, n = 303; saline, n = 294). At week 8, improvement from baseline was significantly greater (P < 0.001) with NOV03 versus saline for tCFS (least square [LS] mean treatment difference, -0.97; 95% confidence interval [CI]: -1.40, -0.55) and VAS dryness score (-7.6; 95% CI: -11.8, -3.4). Improvement from baseline also significantly (P < 0.01) favored NOV03 on all key secondary end points: LS mean treatment difference (95% CI) was -4.7 (-8.2, -1.2) for VAS dryness score at week 2, -0.6 (-0.9, -0.2) for tCFS at week 2, -5.5 (-9.5, -1.6) for VAS burning or stinging score at week 8, and -0.2 (-0.4, -0.1) for cCFS at week 8. Most ocular adverse events (AEs) were mild in severity; no serious ocular AEs occurred. One patient discontinued NOV03 because of an AE (eye irritation). In patients with DED associated with MGD, NOV03 demonstrated statistically significant and clinically meaningful improvements versus hypotonic saline in signs and symptoms of DED and was well tolerated. Proprietary or commercial disclosure may be found after the references.